Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177684 · ClinicalTrials.gov registry record · Phase 3
Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)
A Phase 3 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 3
- Development phase
- 48
- Enrollment target
NCT00177684 is a Phase 3 study that has completed, run by University of Pittsburgh. The registered enrollment target is 48 participants.
The verdict
NCT00177684, a Phase 3 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the optimal delivery system for the nebulization of the lipid complex amphotericin B (Abelcet ®) in lung transplant recipients who are positive for invasive aspergillosis (IA) in their lungs. Additionally, the investigators hope to determine the concentrations of amphotericin B achieved in the epithelial lining fluid, and serum with the administration of four days of lipid complex of amphotericin B (Abelcet ®) (QD) via aerosolized nebulization
Interventions
- DRUG Amphotericin B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00177684
The ClinicalTrials.gov registry entry for NCT00177684 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Amphotericin B is the first listed.
NCT00177684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00177684 about?
NCT00177684 is a clinical study titled "Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)". The purpose of this study is to determine the optimal delivery system for the nebulization of the lipid complex amphotericin B (Abelcet ®) in lung transplant recipients who are positive for invasive aspergillosis (IA) in their lungs. Additionally, the investigators hope to determine the concentratio...
What is the current status of trial NCT00177684?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 48 participants. The study started on 2004-09. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00177684?
The interventions under investigation include: Amphotericin B (DRUG).
Who is sponsoring clinical trial NCT00177684?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.